Abstract 3152
Background
In the single-arm, open-label, multicentre, international phase II trial (NCT02155647 Part A), metastatic Merkel cell carcinoma (mMCC) patients received second-line or later avelumab 10 mg/kg every two weeks. Health-related quality of life (HRQoL) was assessed using the skin cancer-specific FACT-M and the generic EQ-5D. We report HRQoL results 36 months after enrolment of the last patient with focus on HRQoL deterioration-free survival (QFS) rates.
Methods
HRQoL data were obtained at baseline, week 7, and every 6 weeks until disease progression and/or treatment discontinuation. QFS was defined as the time interval between first dose and HRQoL deterioration event i.e. when a HRQoL domain score (FACT-M/EQ VAS) decreased from baseline equivalent to the minimal important difference (MID) threshold, with no further improvement thereafter. For sensitivity analyses, two thresholds are applied termed as minimum and maximum MID. QFS rates were derived from Kaplan-Meier curves and could be interpreted as the likelihood of a patient to endure a time period without relevant HRQoL deterioration until a certain time point.
Results
Based on the intention-to-treat population (n = 88), QFS rates ranged from 40.6% (FACT-M functional well-being, FWB) to 56.3% (EQ VAS) at 12 months when applying minimum MIDs (Table). At 36 months, rates ranged from 20.7% (FWB) to 37.7% (FACT-M social well-being). When applying the maximum MID, QFS rates ranged from 48.6% to 64.9% at 12 months, and 25.3% to 42.7% at 36 months.Table:
1320P HRQoL deterioration-free survival rates (QFS) by time interval (12, 24, 36 months) based on EQ VAS and FACT-M scores applying (negative) minimum/maximum Minimal Important Difference (MID) thresholds, ITT population (N = 88)
MID thresholds1 (min./max.) | HRQoL deterioration-free survival rates (%) | ||||||
---|---|---|---|---|---|---|---|
Minimum MID | Maximum MID | ||||||
Month 12 | Month 24 | Month 36 | Month 12 | Month 24 | Month 36 | ||
EQ-5D | |||||||
EQ VAS | -7 / -10 | 56.3 | 47.4 | 34.8 | 59.0 | 45.5 | 38.5 |
FACT-M | |||||||
Physical well-being (PWB) | -1 / -3 | 46.7 | 43.0 | 36.4 | 52.6 | 46.1 | 35.8 |
Social/Family well-being (SWB) | -1/ -3 | 44.0 | 37.7 | 37.7 | 49.5 | 49.5 | 40.5 |
Emotional well-being (EWB) | -1 / -3 | 49.2 | 41.0 | 32.8 | 55.9 | 51.2 | 42.7 |
Functional well-being (FWB) | -2 / -4 | 40.6 | 32.6 | 20.7 | 52.8 | 48.5 | 33.6 |
Melanoma subscale (MS) | -2 / -5 | 49.7 | 45.7 | 37.4 | 64.9 | 49.1 | 38.2 |
Melanoma surgery scale (MSS) | -2 / -3 | 51.4 | 51.4 | 36.7 | 48.6 | 48.6 | 34.7 |
Trial Outcome Index (TOI) | -4 / -9 | 50.4 | 38.2 | 31.2 | 61.2 | 42.1 | 32.7 |
FACT-G Total Score | -4 / -8 | 46.8 | 37.7 | 24.0 | 51.7 | 43.4 | 27.6 |
FACT-M Total Score | -5 / -12 | 46.6 | 37.6 | 23.9 | 56.9 | 39.7 | 25.3 |
Published in Bharmal, et al. (2017). "Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma." Health Qual Life Outcomes 15(1): 247. Legend: HRQoL=Health-Related Quality of Life; QFS=HRQoL deterioration-free survival rate; MID=Minimal Important Difference; ITT=Intention-to-treat population; VAS=visual analogue scale; EQ VAS=VAS of the EQ-5D questionnaire
Conclusions
As expected, QFS rates decreased over time; however, in the context of an aggressive cancer such as mMCC, various HRQoL domains show promising QFS rates suggesting a substantial proportion of patients reported stable or improved HRQoL on treatment with avelumab across time points, aligned with the clinical efficacy results throughout the long study follow-up of over 36 months.
Clinical trial identification
NCT02155647.
Editorial acknowledgement
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
This study was sponsored by Merck Healthcare KGaA, Darmstadt, Germany, and is part of an alliance between Merck Healthcare KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA.
Disclosure
S.P. D’Angelo: Advisory / Consultancy: Incyte; Advisory / Consultancy: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Nektar; Advisory / Consultancy: Amgen; Advisory / Consultancy, Travel / Accommodation / Expenses: EMD Serono; Advisory / Consultancy: GSK; Advisory / Consultancy: ImmuneDesign; Travel / Accommodation / Expenses: Adaptimmune. S. Nolte: Full / Part-time employment, Employee of ICON plc, which is a paid consultant to the study sponsor: ICON plc. M. Schlichting: Full / Part-time employment: Merck Healthcare KGaA. M. Henry-Szatkowski: Full / Part-time employment, Employee of ICON plc, which is a paid consultant to the study sponsor: ICON plc. M. Hennessy: Full / Part-time employment: EMD Serono, Inc. M. Bharmal: Full / Part-time employment: Merck Healthcare KGaA.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract